Heart failure & cardiomyopathies
MicroRNAs As Novel Biomarkers and Potential Therapeutic Options for Inflammatory Cardiomyopathy
Authors' conclusion
The identification of specific miRNAs offers a novel diagnostic perspective for recognizing intramyocardial inflammation within virus-negative DCMi patients.
Study context
- Population
- Patients with unexplained HF diagnosed by endomyocardial biopsy, plus healthy donors152 patient serum samples
- Participants
- 38 / 24 / 44 / 46 / 10
- Comparison
- Serum miRNA profiles in DCMi vs DCM, inflammation with viral infection, viral infection without inflammation, and healthy donors
- DCMin = 38
- DCMn = 24
- Inflammation with viral infectionn = 44
- Viral infection onlyn = 46
- Healthy donorsn = 10
- Outcome
- Identification and assessment of specific miRNAs in virus-negative DCMi
Performance
As reported in the abstract
Serum miRNA expression (754 miRNAs, TaqMan OpenArray)
miR-1, miR-23, miR-142-5p, miR-155, miR-193 and miR-195 down-regulated only in DCMi
P < 0.005
These microRNAs (miRNAs) differentiated DCMi from all other groups
P < 0.005
Specificity
surpassing 86%
Original publication
MicroRNAs As Novel Biomarkers and Potential Therapeutic Options for Inflammatory Cardiomyopathy. ESC Heart Fail. Published 7 September 2023. doi:10.
Summarised from the published abstract; every number is checked against it